Karolinska Development AB
Jim Van heusden appointed CEO of Karolinska Development

DGAP-News: Karolinska Development AB

2015-03-03 / 08:00

---------------------------------------------------------------------

STOCKHOLM - March 3, 2015. Karolinska Development (STO: KDEV) today announces
that Jim Van heusden has been appointed as CEO. Following the appointment,
Acting CEO Terje Kalland will resume his position as Deputy CEO and Chief
Scientific Officer. 

'We are happy to welcome Jim Van heusden as CEO', says Karolinska Development's
Chairman Bo Jesper Hansen. 'Jim has with his background as a venture capital
entrepreneur an extensive international experience of fundraising and
deal-making in the biotech industry, as well as a deep knowledge of drug
research and development. This is a perfect combination for Karolinska
Development, where innovative financing solutions continuously are important
for the successful development of the portfolio companies'. 

Prior to joining Karolinska Development, Jim founded his own company bioskills
in 2013, providing an entrepreneurial approach towards fundraising and
strategic advice for biotech companies and life science funds. From 2001 to
2013, he held various positions at Gimv focusing on investments in life
sciences, and since 2007 as a partner, Jim has an excellent and proven track
record in building successful companies.  Prior to joining Gimv, he was working
as a senior scientist at the department of Oncology at Janssen Pharmaceutical,
a Johnson & Johnson company. Jim is a Belgian citizen and has a PhD in
molecular and cellular biology from the University of Maastricht. 

'With the implementation of our new strategy that will transform Karolinska
Development into a successful venture vehicle, Jim comes to us with an
entrepreneurial attitude, and a strong and successful track record within both
drug discovery and development and venture capital. Jim was at Gimv responsible
for deal sourcing, due diligence, several direct investments in both public and
private companies, significant exits (IPO and M&A), divestments, fundraising,
syndicate building, valuation, portfolio management and reporting, business
strategy and development', says Bo Jesper Hansen. 

'Beyond that, Jim has an extensive experience as a project manager within drug
discovery and development. With this impressive background, and Jim's
commitment to Karolinska Development, I am confident that we have secured the
right competence, skills and attitude to drive Karolinska Development forward
to future successes', continues Bo Jesper Hansen. 

Jim Van heusden, the new CEO at Karolinska Development, says: 'The combination
of top-notch high-quality science coming from Karolinska Institutet, coupled
with a supportive team and board makes this a very exciting opportunity.  I am
thrilled about joining to further unlock the value of the existing portfolio by
attracting new investments from international co-investors.  Karolinska
Development will continue to create and build new companies to bring
high-quality science and innovation to patients, thereby creating value for our
shareholders'. 

Jim Van heusden will assume his new position and take over from acting CEO
Terje Kalland from March 3, 2015. Terje Kalland will reassume his position as
Deputy CEO and Chief Scientific Officer. 'The board would like to thank Terje
Kalland for taking the role as acting CEO of the company while we were
searching for a permanent solution', says Bo Jesper Hansen. 



For further information, please contact:
Bo Jesper Hansen, Chairman of the Board, Karolinska Development AB
Phone: +46 72 245 98 92





TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers,
investors and society by developing innovations from world class science into
differentiated products that can be partnered. The business model is to: SELECT
the most commercially attractive medical innovations that can potentially
satisfy unmet medical needs; DEVELOP innovations to the stage where the
greatest return on investment can be achieved; and COMMERCIALIZE the
innovations through the sale of companies or out-licensing of products. An
exclusive deal flow agreement with Karolinska Institutet Innovations AB, along
with other cooperation agreements with leading universities, delivers a
continuous flow of innovations. For more information, please visit
www.karolinskadevelopment.com. 

Karolinska Development is listed on NASDAQ OMX (STO: KDEV). Karolinska
Development may be required to disclose the information provided herein
pursuant to the Securities Markets Act.
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-03-03 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                    
Company:     Karolinska Development AB  
 
 
             Sweden                     
ISIN:        SE0002190926               
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
328995 2015-03-03